Lupus nephritis in African Americans

American Journal of the Medical Sciences

Volumn 323, Issue 2, 2002, Pages 85-89

  Lea, Janice P ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; Lupus nephritis

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE COURSE; ENVIRONMENTAL FACTOR; FEMALE; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NEGRO; PATHOGENESIS; PROGNOSIS; PROTEINURIA; SOCIOECONOMICS;

EID: 0036088316     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200202000-00005     Document Type: Conference Paper

References (38)

1. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus
2. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death
3. The prognosis of lupus nephritis in African-Americans: A retrospective analysis
4. Factors predictive of outcome in severe lupus nephritis
5. High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients
6. Hypertension increases the risk of renal deterioration in systemic lupus erythematosus
7. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
8. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
9. Significance of enzyme-linked immunosorbent assay (ELISA) for antibodies to double-stranded DNA in patients with Lupus nephritis: Correlation with severity of renal histology
10. Lupus nephritis: Association between serology and renal biopsy measures
11. A distinctive autoantibody profile in black female patients with lupus nephritis
12. Autoantibody profile in African-American patients with lupus nephritis
13. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis
14. Familial clustering of end-stage renal disease in blacks with lupus nephritis
15. Alleles are heritable risk factors for lupus nephritis in African-Americans
16. Immunopathogenic mechanisms of glomerular injury
17. Mechanisms of progression of renal damage in lupus nephritis: Pathogenesis of renal scarring
18. Effects of transforming growth factor-beta 1 on renal extracellular matrix components and their regulating proteins
19. Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
20. Renal TGF-β in HIV-associated kidney diseases
21. TGF-β in kidney fibrosis: A target for gene therapy
22. Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy
23. Expression of types I, II, and III TGF-β receptors in human glomerulonephritis
24. Transforming growth factor-β1 hyperexpression in African-American end-stage renal disease patients
25. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis
26. Persistent lupus activity in end-stage renal disease
27. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis
28. Antiphospholipid antibody syndrome in renal transplantation: Occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus
29. Access to renal transplantation among patients with end-stage renal disease due to lupus nephritis
30. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era
31. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
32. Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients
33. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
34. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
35. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study
36. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
37. Effects of blood pressure control on progressive renal disease in blacks and whites
38. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995